LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 63

Search options

  1. Article ; Online: Current Treatment Options for Cystic Fibrosis-Related Liver Disease.

    Staufer, Katharina

    International journal of molecular sciences

    2020  Volume 21, Issue 22

    Abstract: Cystic Fibrosis-related liver disease (CFLD) has become a leading cause of morbidity and mortality in patients with Cystic Fibrosis (CF), and affects children and adults. The understanding of the pathogenesis of CFLD is key in order to develop ... ...

    Abstract Cystic Fibrosis-related liver disease (CFLD) has become a leading cause of morbidity and mortality in patients with Cystic Fibrosis (CF), and affects children and adults. The understanding of the pathogenesis of CFLD is key in order to develop efficacious treatments. However, it remains complex, and has not been clarified to the last. The search for a drug might be additionally complicated due to the diverse clinical picture and lack of a unified definition of CFLD. Although ursodeoxycholic acid has been used for decades, its efficacy in CFLD is controversial, and the potential of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators and targeted gene therapy in CFLD needs to be defined in the near future. This review focuses on the current knowledge on treatment strategies for CFLD based on pathomechanistic viewpoints.
    MeSH term(s) Cystic Fibrosis/complications ; Cystic Fibrosis/genetics ; Cystic Fibrosis/metabolism ; Cystic Fibrosis/therapy ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; Cystic Fibrosis Transmembrane Conductance Regulator/metabolism ; Humans ; Liver Diseases/etiology ; Liver Diseases/genetics ; Liver Diseases/metabolism ; Liver Diseases/pathology ; Ursodeoxycholic Acid/therapeutic use
    Chemical Substances CFTR protein, human ; Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6) ; Ursodeoxycholic Acid (724L30Y2QR)
    Language English
    Publishing date 2020-11-14
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms21228586
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?

    Staufer, Katharina / Stauber, Rudolf E

    Biomedicines

    2023  Volume 11, Issue 8

    Abstract: Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), both of them accounting for fatty liver disease (FLD), are among the most common chronic liver diseases globally, contributing to substantial public health burden. Both ... ...

    Abstract Non-alcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD), both of them accounting for fatty liver disease (FLD), are among the most common chronic liver diseases globally, contributing to substantial public health burden. Both NAFLD and ALD share a similar picture of clinical presentation yet may have differences in prognosis and treatment, which renders early and accurate diagnosis difficult but necessary. While NAFLD is the fastest increasing chronic liver disease, the prevalence of ALD has seemingly remained stable in recent years. Lately, the term steatotic liver disease (SLD) has been introduced, replacing FLD to reduce stigma. SLD represents an overarching term to primarily comprise metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), as well as alcohol-related liver disease (ALD), and MetALD, defined as a continuum across which the contribution of MASLD and ALD varies. The present review discusses current knowledge on common denominators of NAFLD/MASLD and ALD in order to highlight clinical and research needs to improve our understanding of SLD.
    Language English
    Publishing date 2023-07-26
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines11082108
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Current Treatment Options for Cystic Fibrosis-Related Liver Disease

    Katharina Staufer

    International Journal of Molecular Sciences, Vol 21, Iss 8586, p

    2020  Volume 8586

    Abstract: Cystic Fibrosis-related liver disease (CFLD) has become a leading cause of morbidity and mortality in patients with Cystic Fibrosis (CF), and affects children and adults. The understanding of the pathogenesis of CFLD is key in order to develop ... ...

    Abstract Cystic Fibrosis-related liver disease (CFLD) has become a leading cause of morbidity and mortality in patients with Cystic Fibrosis (CF), and affects children and adults. The understanding of the pathogenesis of CFLD is key in order to develop efficacious treatments. However, it remains complex, and has not been clarified to the last. The search for a drug might be additionally complicated due to the diverse clinical picture and lack of a unified definition of CFLD. Although ursodeoxycholic acid has been used for decades, its efficacy in CFLD is controversial, and the potential of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators and targeted gene therapy in CFLD needs to be defined in the near future. This review focuses on the current knowledge on treatment strategies for CFLD based on pathomechanistic viewpoints.
    Keywords cystic fibrosis-related liver disease ; CFTR modulators ; ursodeoxycholic acid ; liver transplantation ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Subject code 610
    Language English
    Publishing date 2020-11-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Detection of unreported alcohol consumption in fatty liver disease.

    Staufer, Katharina / Mangal, Brian / Trauner, Michael

    Journal of hepatology

    2022  Volume 78, Issue 2, Page(s) e67–e69

    MeSH term(s) Humans ; Non-alcoholic Fatty Liver Disease/epidemiology ; Non-alcoholic Fatty Liver Disease/etiology ; Alcohol Drinking/adverse effects
    Language English
    Publishing date 2022-10-27
    Publishing country Netherlands
    Document type Letter ; Comment
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2022.10.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: MASLD is related to impaired alcohol dehydrogenase (ADH) activity and elevated blood ethanol levels: Role of TNFα and JNK.

    Burger, Katharina / Jung, Finn / Staufer, Katharina / Ladurner, Ruth / Trauner, Michael / Baumann, Anja / Brandt, Annette / Bergheim, Ina

    Redox biology

    2024  Volume 71, Page(s) 103121

    Abstract: Elevated fasting ethanol levels in peripheral blood frequently found in metabolic dysfunction-associated steatohepatitis (MASLD) patients even in the absence of alcohol consumption are discussed to contribute to disease development. To test the ... ...

    Abstract Elevated fasting ethanol levels in peripheral blood frequently found in metabolic dysfunction-associated steatohepatitis (MASLD) patients even in the absence of alcohol consumption are discussed to contribute to disease development. To test the hypothesis that besides an enhanced gastrointestinal synthesis a diminished alcohol elimination through alcohol dehydrogenase (ADH) may also be critical herein, we determined fasting ethanol levels and ADH activity in livers and blood of MASLD patients and in wild-type ± anti-TNFα antibody (infliximab) treated and TNFα
    MeSH term(s) Mice ; Humans ; Animals ; Alcohol Dehydrogenase/genetics ; Alcohol Dehydrogenase/metabolism ; Tumor Necrosis Factor-alpha/genetics ; Infliximab/pharmacology ; Ethanol/adverse effects ; Fatty Liver ; Alcohol Drinking
    Chemical Substances Alcohol Dehydrogenase (EC 1.1.1.1) ; Tumor Necrosis Factor-alpha ; Infliximab (B72HH48FLU) ; Ethanol (3K9958V90M)
    Language English
    Publishing date 2024-03-12
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2701011-9
    ISSN 2213-2317 ; 2213-2317
    ISSN (online) 2213-2317
    ISSN 2213-2317
    DOI 10.1016/j.redox.2024.103121
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Regression of Graft Steatosis After Liver Transplantation.

    Meyer, Helene / Maurer, Martin H / Staufer, Katharina / Berzigotti, Annalisa / Banz, Vanessa

    Progress in transplantation (Aliso Viejo, Calif.)

    2022  Volume 32, Issue 4, Page(s) 321–326

    Abstract: Introduction: ...

    Abstract Introduction:
    MeSH term(s) Humans ; Liver Transplantation/adverse effects ; Liver Transplantation/methods ; Retrospective Studies ; Fatty Liver/pathology ; Liver/diagnostic imaging ; Tissue Donors ; Biopsy ; Graft Survival
    Language English
    Publishing date 2022-08-31
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2864264-8
    ISSN 2164-6708 ; 1526-9248
    ISSN (online) 2164-6708
    ISSN 1526-9248
    DOI 10.1177/15269248221122868
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Corrigendum to "Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease" [J Hepatol 77 (2022) 918-930].

    Staufer, Katharina / Huber-Schönauer, Ursula / Strebinger, Georg / Pimingstorfer, Philipp / Suesse, Silke / Scherzer, Thomas-Matthias / Paulweber, Bernhard / Ferenci, Peter / Stimpfl, Thomas / Yegles, Michel / Datz, Christian / Trauner, Michael

    Journal of hepatology

    2023  Volume 78, Issue 5, Page(s) 1080–1083

    Language English
    Publishing date 2023-03-13
    Publishing country Netherlands
    Document type Published Erratum
    ZDB-ID 605953-3
    ISSN 1600-0641 ; 0168-8278
    ISSN (online) 1600-0641
    ISSN 0168-8278
    DOI 10.1016/j.jhep.2023.01.018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Author's Reply to "Liver Dysfunction with Both Roux-en-Y and One Anastomosis Gastric Bypass Is Almost Exclusively Seen with Longer Than Standard Limb Lengths" by Kamal K. Mahawar.

    Staufer, Katharina / Eilenberg, Magdalena / Prager, Gerhard

    Obesity surgery

    2018  Volume 29, Issue 1, Page(s) 301–302

    MeSH term(s) Anastomosis, Roux-en-Y ; Bariatric Surgery ; Gastric Bypass ; Humans ; Liver Diseases ; Obesity, Morbid/surgery
    Language English
    Publishing date 2018-11-05
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1070827-3
    ISSN 1708-0428 ; 0960-8923
    ISSN (online) 1708-0428
    ISSN 0960-8923
    DOI 10.1007/s11695-018-3566-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Biomarkers for detection of alcohol consumption in liver transplantation.

    Staufer, Katharina / Yegles, Michel

    World journal of gastroenterology

    2016  Volume 22, Issue 14, Page(s) 3725–3734

    Abstract: Alcoholic liver disease is an established, yet controversial, indication for liver transplantation. Although an abstinence period of up to 6 mo prior to transplantation is mandatory, alcohol relapse after transplantation is a common event. In case of ... ...

    Abstract Alcoholic liver disease is an established, yet controversial, indication for liver transplantation. Although an abstinence period of up to 6 mo prior to transplantation is mandatory, alcohol relapse after transplantation is a common event. In case of recurrence of heavy drinking, graft survival is significantly impaired. Guidelines on detection and surveillance of alcohol consumption in this patient cohort are lacking. This review summarizes the challenge of patient selection as well as the current knowledge on established and novel alcohol biomarkers with special focus on liver transplant candidates and recipients.
    MeSH term(s) Alcohol Abstinence ; Alcohol Drinking/adverse effects ; Alcohol Drinking/metabolism ; Alcohol Drinking/prevention & control ; Biomarkers/metabolism ; Graft Survival ; Humans ; Liver Diseases, Alcoholic/diagnosis ; Liver Diseases, Alcoholic/etiology ; Liver Diseases, Alcoholic/surgery ; Liver Transplantation/adverse effects ; Postoperative Complications/prevention & control ; Predictive Value of Tests ; Recurrence ; Risk Factors ; Time Factors ; Treatment Outcome
    Chemical Substances Biomarkers
    Language English
    Publishing date 2016-04-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2185929-2
    ISSN 2219-2840 ; 1007-9327
    ISSN (online) 2219-2840
    ISSN 1007-9327
    DOI 10.3748/wjg.v22.i14.3725
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver disease.

    Baumann, Anja / Rajcic, Dragana / Brandt, Annette / Sánchez, Victor / Jung, Finn / Staltner, Raphaela / Nier, Anika / Trauner, Michael / Staufer, Katharina / Bergheim, Ina

    Journal of cellular and molecular medicine

    2022  Volume 26, Issue 4, Page(s) 1206–1218

    Abstract: Changes in intestinal nitric oxide metabolism are discussed to contribute for the development of intestinal barrier dysfunction in non-alcoholic fatty liver disease (NAFLD). To induce steatosis, female C57BL/6J mice were pair-fed with a liquid control ... ...

    Abstract Changes in intestinal nitric oxide metabolism are discussed to contribute for the development of intestinal barrier dysfunction in non-alcoholic fatty liver disease (NAFLD). To induce steatosis, female C57BL/6J mice were pair-fed with a liquid control diet (C) or a fat-, fructose- and cholesterol-rich diet (FFC) for 8 weeks. Mice received the diets ± 2.49 g L-arginine/kg bw/day for additional 5 weeks. Furthermore, mice fed C or FFC ± L-arginine/kg bw/day for 8 weeks were concomitantly treated with the arginase inhibitor N
    MeSH term(s) Animals ; Arginine/metabolism ; Arginine/pharmacology ; Female ; Homeostasis ; Humans ; Liver/metabolism ; Mice ; Mice, Inbred C57BL ; Nitric Oxide/metabolism ; Non-alcoholic Fatty Liver Disease/etiology ; Non-alcoholic Fatty Liver Disease/metabolism ; Toll-Like Receptor 4/metabolism
    Chemical Substances Toll-Like Receptor 4 ; Nitric Oxide (31C4KY9ESH) ; Arginine (94ZLA3W45F)
    Language English
    Publishing date 2022-01-14
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2074559-X
    ISSN 1582-4934 ; 1582-4934 ; 1582-1838
    ISSN (online) 1582-4934
    ISSN 1582-4934 ; 1582-1838
    DOI 10.1111/jcmm.17175
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top